This stock came up in my scans. I like the science and the results so far. I am planning to take a position tomorrow morning. I am just afraid it might pull back as soon as I enter. What is your average cost for MEIP? Thanks man and good to see you again after a long time :)
Juno has a market cap of 4 billion while this is still at 600 million. Once BLCM gets some attention, it will move and could move fast because of the small float.
Brian, do you mean 15th holding by number of shares or by $ value of the holding. Also, how did you come up 15th. I am looking at whale wisdom and its hard to say what position should it be at. Thanks.
We have 3 days left in the week. And I think we will end up north of .40
Oh I see, I was under the impression they will buy $20 million worth of stock. But seems like its UP TO $20 million. Yeah, I also hope the share count does not go up too much too fast. I think regarding the warrants that BB have, that may come into picture once we are in double digits.
Using the current market cap, I come up with 91 million shares outstanding. Including today's offering 20 M shares, total outstanding shares is around 111 million. Bakers can own 5% tops. They own around 1.6 M and if they end up buying $20 million worth of the offering, they will add another 4.9 miilion shares. But that adds up to 6.5 million shares with a float of 111 million which comes out to be 5.85%
The only way it could work is if IDRA includes the outstanding warrants in the calculation. What are your thoughts about this?
Saratoga, here's a copy paste from an article. If GILD is going after Hep B, chances are they will get approved and get approved faster since they are in phase 3. Something to do more due diligence on .
At the moment, there are a few notable names developing hepatitis B compounds, including Arrowhead Research (NASDAQ: ARWR ) , which is developing RNA-interference candidate ARC-520. Although interim phase 2a data failed to impress Wall Street, the company is testing its drug at higher doses in the hope of seeing better efficacy. We should know a lot more about ARC-520 in 2015, but for now, results are not promising.
Now here's the kicker about hepatitis B. The other major compounds to watch come from -- drumroll please -- Gilead Sciences. That's right; I'm suggesting that Gilead Sciences might be the next Gilead Sciences, and that its ascent may be nowhere near complete. The company has three HBV compounds in its pipeline at the moment, and the one with the most Wall Street attention, GS-9620, is expected to have results in the latter half of 2015.
With the exception of Biogen Idec, there may not be another Gilead out there... except for Gilead itself, which could still benefit from improving HCV sales, as well as growth in Stribild, its four-in-one HIV drug.
Hey Bird, I started a position in CERS at 5.65. The thing is I bought it on margin and I am hoping for a quick move :) I see some strength since it closed above 50 day MA. Where do you see it in next week or two. TIA
Saratoga, if I am not mistaken, isnt GILD jumping on to a phase 3 directly from phase 1 for Hep B cure? I know that TKMR is also in the race
Hey Chanley, I am too lazy to look that up. Can you tell me more about the pricing. TIA